ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0971

Longitudinal CyTOF Immunophenotyping Reveals Distinct Patterns of T cell-B Cell Dysregulation in SLE

Takanori Sasaki1, Sabrina Bracero1, Lin Chen1, Ye Cao2, Emma Stevens1, Yujie Qu3, Guoxing Wang4, Joshua Keegan1, James Lederer5, Stephen Alves3, Karen Costenbader6 and Deepak Rao2, 1Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Merck & Co., Inc., Boston, MA, 4Merck & Co., Inc, Boston, MA, 5Brigham and Women's Hospital and Harvard Medical School, Millis, MA, 6Brigham and Women's Hospital, Belmont, MA

Meeting: ACR Convergence 2021

Keywords: Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Abstracts: SLE – Etiology & Pathogenesis (0970–0973)

Session Type: Abstract Session

Session Time: 2:15PM-2:30PM

Background/Purpose: Mass cytometry (CyTOF), a powerful tool to broadly assess immuno-phenotypes, has previously revealed that T follicular helper (Tfh) cells, T peripheral helper (Tph) cells, and age-associated B cells (ABCs) are robustly expanded in patients with newly diagnosed SLE. However, how these and other immune cell populations change over time in SLE remains unclear.

Methods: We employed CyTOF with two 39 marker panels (T and B cell) in cryopreserved peripheral blood mononuclear cells (PBMCs) from 9 patients with newly diagnosed immunosuppressant-naïve SLE, 15 patients with established SLE, and 14 non-inflammatory controls. FlowSOM (Flow Self-Organizing Maps) and marker analysis by tSNE (t-distributed Stochastic Neighbor Embedding) used to identify and quantify clusters based on their 39-parameter characterization. For the newly diagnosed cohort, PBMCs were analyzed at 3 time points (A = at diagnosis, B = 6 months after the diagnosis, C = 12 months after the diagnosis). Serum samples were also analyzed to quantify 65 cytokines by Luminex multiplex assay, and associations between cell types and cytokines assessed by Spearman correlation.

Results: We first confirmed that among CD4 T cells, Tfh cells (PD-1hi CXCR5+ CD4+ T cells) and Tph cells (PD-1hi CXCR5– CD4+ T cells) were significantly increased in SLE patients. A broad analysis of B cells identified 3 clusters as significantly increased in the patients with SLE. Two of these clusters contained CD11c+ CD21– ABCs, consistent with prior analyses. A third cluster, cluster 8, contained a CD19int Ki67hi B cell population. This CD19int Ki67hi cluster was also CD21low, CD11clow, CD27hi, and CD38hi, consistent with a Ki67hi plasmablast population (Figure1A). Among CD8 T cells, we identified one highly expanded cluster in SLE patients compared to controls, which expressed Ki67hi, ICOShi, PD-1int, CD57low, and granzyme Bint (Figure1B). In longitudinal analyses, the frequency of Tfh cells decreased over the first year of SLE, while Tph cells, ABCs, CD19int Ki67hi plasmablasts, and Ki67+ ICOS+ CD8 T cells remained elevated at 12 months (Figure 2A). Tph cells, but not Tfh cells, were correlated with ABCs (r = 0.53, p = 0.004) and CD19int Ki67hi PB (r = 0.39, p = 0.042). Ki67+ ICOS+ CD8 T cells were correlated with Tph cells and Tfh cells, but more strongly in Tph cells (r = 0.68, p < 0.0001) (Figure 2B). Correlation analyses including both immune cell frequencies and cytokines revealed an association of Tph cells, Ki67+ ICOS+ CD8 T cells, ABCs, and CD19int Ki67hi plasmablasts. These associated populations, but not Tfh cells, were also significantly correlated with CXCL13 and TSLP (Figure 3).

Conclusion: Tph cells, ABCs, and the two different Ki67+ proliferating populations were consistently elevated during the first year after diagnosis of SLE, while Tfh cells decreased in frequency over the same timeframe. This longitudinal immunophenotyping and cytokine profiling approach thus highlights persistent activation of a Tph-CXCL13-ABC- plasmablasts axis in both early and established phases of SLE.

Figure 1.jpeg”

Figure 1. Expanded two Ki67+ populations in PBMCs of SLE patients. A. tSNE plot of CD19+ cells revealed that CD21low, CD11clow, CD27hi, CD38hi plasmablasts were expanded in SLE (Cluster 8). B. tSNE plot of CD8+ cells revealed that Ki67hi, ICOShi, PD_1int, CD57low, GrzBint CD8 T cells were expanded in SLE (Cluster 9).Figure 1. Expanded two Ki67+ populations in PBMCs of SLE patients. A. tSNE plot of CD19+ cells revealed that CD21low, CD11clow, CD27hi, CD38hi plasmablasts were expanded in SLE (Cluster 8). B. tSNE plot of CD8+ cells revealed that Ki67hi, ICOShi, PD_1int, CD57low, GrzBint CD8 T cells were expanded in SLE (Cluster 9).

Figure 2.jpeg”

Figure 2. Longitudinal CyTOF analysis of PBMCs in SLE patients. A. Time course changes of Tph, Tfh, ABCs, CD19int Ki67hi plasmablasts, and Ki67+ ICOS+ CD8 T cells in SLE. Timepoint A = at diagnosis, timepoint B = 6 months after the diagnosis, timepoint C = 12 months after the diagnosis. B. Correlation analysis between dysregulated T cell, B cell subsets and cytokine in SLE. HC and A were compared by Mann-Whitney U test. A, B, and C were compared by Wilcoxon test. *p<0.05, **p<0.01, ***p<0.001. Correlation was assessed by Spearman’s test.

Figure 3.jpeg”

Figure 3. A hierarchical clustering heatmap with immune cell frequencies and cytokines in SLE. Among 65 cytokines, 31 cytokines were detected. Correlation coefficients calculated by Spearman’s test were used for the heatmap. *p<0.05 in Tph cells, Ki67+ ICOS+ CD8 T cells, ABCs, and CD19int Ki67hi plasmablasts, but not in Tfh cells and other populations.


Disclosures: T. Sasaki, None; S. Bracero, None; L. Chen, None; Y. Cao, None; E. Stevens, None; Y. Qu, Merck & Co., Inc., 3; G. Wang, Merck & Co., Inc., 3; J. Keegan, None; J. Lederer, None; S. Alves, Merck & Co., Inc., 3; K. Costenbader, Neutrolis, 11, Merck, Exagen, Gilead, 5, Astra Zeneca, Neutrolis, 2; D. Rao, Janssen, 5, 6, Bristol-Myers Squibb, 1, 5, Scipher Medicine, 2, Pfizer, 6, Merck, 6.

To cite this abstract in AMA style:

Sasaki T, Bracero S, Chen L, Cao Y, Stevens E, Qu Y, Wang G, Keegan J, Lederer J, Alves S, Costenbader K, Rao D. Longitudinal CyTOF Immunophenotyping Reveals Distinct Patterns of T cell-B Cell Dysregulation in SLE [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/longitudinal-cytof-immunophenotyping-reveals-distinct-patterns-of-t-cell-b-cell-dysregulation-in-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/longitudinal-cytof-immunophenotyping-reveals-distinct-patterns-of-t-cell-b-cell-dysregulation-in-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology